OBJECTIVES: To test two interventions to reduce interleukin (IL)-6 levels, an indicator of low-grade chronic inflammation and an independent risk factor for impaired mobility and slow walking speed in older adults. DESIGN: The ENabling Reduction of low-Grade Inflammation in SEniors (ENRGISE) Pilot Study was a multicenter, double-blind, placebo-controlled randomized pilot trial of two interventions to reduce IL-6 levels. SETTING:Five university-based research centers. PARTICIPANTS: Target enrollment was 300 men and women aged 70 and older with an average plasma IL-6 level between 2.5 and 30 pg/mL measured twice at least 1 week apart. Participants had low to moderate physical function, defined as self-reported difficulty walking one-quarter of a mile or climbing a flight of stairs and usual walk speed of less than 1 m/s on a 4-m usual-pace walk. INTERVENTION: Participants were randomized to losartan, omega-3 fish oil (ω-3), combined losartan and ω-3, or placebo. Randomization was stratified depending on eligibility for each group. A titration schedule was implemented to reach a dose that was safe and effective for IL-6 reduction. Maximal doses were 100 mg/d for losartan and 2.8 g/d for ω-3. MEASUREMENTS: IL-6, walking speed over 400 m, physical function (Short Physical Performance Battery), other inflammatory markers, safety, tolerability, frailty domains, and maximal leg strength were measured. RESULTS: Results from the ENRGISE Pilot Study will provide recruitment yields, feasibility, medication tolerance and adherence, and preliminary data to help justify a sample size for a more definitive randomized trial. CONCLUSION: The ENRGISE Pilot Study will inform a larger subsequent trial that is expected to have important clinical and public health implications for the growing population of older adults with low-grade chronic inflammation and mobility limitations.
RCT Entities:
OBJECTIVES: To test two interventions to reduce interleukin (IL)-6 levels, an indicator of low-grade chronic inflammation and an independent risk factor for impaired mobility and slow walking speed in older adults. DESIGN: The ENabling Reduction of low-Grade Inflammation in SEniors (ENRGISE) Pilot Study was a multicenter, double-blind, placebo-controlled randomized pilot trial of two interventions to reduce IL-6 levels. SETTING: Five university-based research centers. PARTICIPANTS: Target enrollment was 300 men and women aged 70 and older with an average plasma IL-6 level between 2.5 and 30 pg/mL measured twice at least 1 week apart. Participants had low to moderate physical function, defined as self-reported difficulty walking one-quarter of a mile or climbing a flight of stairs and usual walk speed of less than 1 m/s on a 4-m usual-pace walk. INTERVENTION: Participants were randomized to losartan, omega-3 fish oil (ω-3), combined losartan and ω-3, or placebo. Randomization was stratified depending on eligibility for each group. A titration schedule was implemented to reach a dose that was safe and effective for IL-6 reduction. Maximal doses were 100 mg/d for losartan and 2.8 g/d for ω-3. MEASUREMENTS: IL-6, walking speed over 400 m, physical function (Short Physical Performance Battery), other inflammatory markers, safety, tolerability, frailty domains, and maximal leg strength were measured. RESULTS: Results from the ENRGISE Pilot Study will provide recruitment yields, feasibility, medication tolerance and adherence, and preliminary data to help justify a sample size for a more definitive randomized trial. CONCLUSION: The ENRGISE Pilot Study will inform a larger subsequent trial that is expected to have important clinical and public health implications for the growing population of older adults with low-grade chronic inflammation and mobility limitations.
Authors: Cem Koz; Oben Baysan; Mehmet Yokusoglu; Mehmet Uzun; Mustafa Yildirim; Adnan Hasimi; Bilgehan Savas Oz; Kursad Erinc; Hayrettin Karaeren; Huseyin Celebi; Ersoy Isik Journal: Med Sci Monit Date: 2009-07
Authors: Savina Nodari; Marco Triggiani; Umberto Campia; Alessandra Manerba; Giuseppe Milesi; Bruno M Cesana; Mihai Gheorghiade; Livio Dei Cas Journal: J Am Coll Cardiol Date: 2011-01-06 Impact factor: 24.094
Authors: Tim Bongartz; Alex J Sutton; Michael J Sweeting; Iain Buchan; Eric L Matteson; Victor Montori Journal: JAMA Date: 2006-05-17 Impact factor: 56.272
Authors: Brenda W J H Penninx; Stephen B Kritchevsky; Anne B Newman; Barbara J Nicklas; Eleanor M Simonsick; Susan Rubin; Michael Nevitt; Marjolein Visser; Tamara Harris; Marco Pahor Journal: J Am Geriatr Soc Date: 2004-07 Impact factor: 5.562
Authors: Rafat A Siddiqui; Saame R Shaikh; Laura A Sech; Heidi R Yount; William Stillwell; Gary P Zaloga Journal: Mini Rev Med Chem Date: 2004-10 Impact factor: 3.862
Authors: Carlo Custodero; Stephen D Anton; Daniel P Beavers; Robert T Mankowski; Stephanie A Lee; Mary M McDermott; Roger A Fielding; Anne B Newman; Russel P Tracy; Stephen B Kritchevsky; Walter T Ambrosius; Marco Pahor; Todd M Manini Journal: Arch Gerontol Geriatr Date: 2020-05-30 Impact factor: 3.250
Authors: C Custodero; R T Mankowski; S A Lee; Z Chen; S Wu; T M Manini; J Hincapie Echeverri; C Sabbà; D P Beavers; J A Cauley; M A Espeland; R A Fielding; S B Kritchevsky; C K Liu; M M McDermott; M E Miller; R P Tracy; A B Newman; W T Ambrosius; M Pahor; S D Anton Journal: Ageing Res Rev Date: 2018-05-25 Impact factor: 10.895
Authors: Marco Pahor; Stephen D Anton; Daniel P Beavers; Jane A Cauley; Roger A Fielding; Stephen B Kritchevsky; Christiaan Leeuwenburgh; Kristina H Lewis; Christine K Liu; Laura C Lovato; Jane Lu; Todd M Manini; Mary M McDermott; Michael E Miller; Anne B Newman; Barbara Radziszewska; Cynthia L Stowe; Russell P Tracy; Michael P Walkup; Samuel S Wu; Walter T Ambrosius Journal: J Gerontol A Biol Sci Med Sci Date: 2019-09-15 Impact factor: 6.053
Authors: Amy C Justice; Kristine M Erlandson; Peter W Hunt; Alan Landay; Paolo Miotti; Russell P Tracy Journal: J Infect Dis Date: 2018-01-30 Impact factor: 5.226
Authors: Jane A Cauley; Todd M Manini; Laura Lovato; Jennifer Talton; Steven D Anton; Kathryn Domanchuk; Kimberly Kennedy; Cynthia L Stowe; Michael Walkup; Roger A Fielding; Stephen B Kritchevsky; Mary M McDermott; Anne B Newman; Walter T Ambrosius; Marco Pahor Journal: J Gerontol A Biol Sci Med Sci Date: 2019-07-12 Impact factor: 6.053
Authors: Daniel P Beavers; Stephen B Kritchevsky; Thomas M Gill; Walter T Ambrosius; Stephen D Anton; Roger A Fielding; Abby C King; W Jack Rejeski; Laura Lovato; Mary M McDermott; Anne B Newman; Marco Pahor; Michael P Walkup; Russell P Tracy; Todd M Manini Journal: J Gerontol A Biol Sci Med Sci Date: 2021-11-15 Impact factor: 6.053